Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.
about
Advances in rheumatology: new targeted therapeuticsReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseAdalimumab for the treatment of rheumatoid arthritisApplication of a stochastic modeling to assess the evolution of tuberculous and non-tuberculous mycobacterial infection in patients treated with tumor necrosis factor inhibitorsCardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)The protective antibodies induced by a novel epitope of human TNF-alpha could suppress the development of collagen-induced arthritis.Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in AsiaBiologics and heart failure in rheumatoid arthritis: are we any wiser?Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.Efficacy and complications of surgery for Crohn's diseaseAbatacept treatment for rheumatoid arthritisDisseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept.Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Tumor necrosis factor inhibitors - state of knowledge.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritisLong-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus().Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.TNFalpha blockade in human diseases: an overview of efficacy and safety.Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.Adalimumab for rheumatoid arthritis.Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE StudyHUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab.Treating psoriasis with adalimumab.Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeLymphoma risk in inflammatory bowel disease: is it the disease or its treatment?Surgical treatment of anorectal crohn disease.
P2860
Q21093257-CA724FC4-A1C2-49FC-BC08-98491D8F69A2Q26822029-98DF0675-AC6A-4645-B9BD-F72CE3783E81Q28282655-1F136DDD-1E3E-4A61-BDFD-4B1895F98368Q28485323-29C74F68-2410-4BC8-9B67-1E7FDF5DC575Q30240180-DCF4EE5A-F402-4278-93CA-A348D8403CB3Q30577403-0F3197EA-30A2-47B3-AA5E-C1608F24EC4DQ31169591-FD93F74C-818F-4201-90BA-6E46EF15F278Q33527432-029032B4-9115-4C38-8C17-2827155110C3Q33667789-166B6387-0880-4ACF-86B2-060E96EB0BC8Q33898103-BFAD1753-BEE8-4707-BCDC-2C12B1E8BCA3Q33939033-6E0A5FCD-753F-4C02-A1AA-A5CA03C879B5Q34076916-EC95801D-7E3C-4350-80F3-5100FF74FC68Q34078707-A4B9022A-5667-4BCF-846A-8EBB0357611AQ34081925-45EB3831-8213-4E5A-8CE9-F079F1D8B949Q34169347-6F405ACE-869C-4446-92AD-FE7BEDDBBA1FQ34293341-C84CF68C-F421-4C7E-9489-07C1D6FB4B92Q34588972-BA280E05-F1E5-4774-B196-2FE7E14464FFQ34607722-5DD0B267-3BF6-469F-B21D-9FA0FF86D3E5Q34620323-62CF01E6-F923-45F7-82D2-2CD6165F54D5Q34974335-9DA88B1E-AFCC-4F39-997B-B0C26CFD1A03Q34984568-21953026-4648-439E-B4E1-807F83112AD6Q35141922-0F43C9AE-9425-4D39-B588-020B3275AD61Q35154359-6CF57E8F-D2D7-4C23-8E74-DAE3A78B3A66Q35208434-940CC2B5-768C-476E-9E2D-CD37EA9BFACFQ35348379-D7D0BAE4-683E-4FDC-AA8B-3B370EA84114Q35638252-27FC2FC3-BE5E-4B04-AD2A-DFC6DB540869Q35953319-10E5BCD0-2B78-4D55-A534-6FC1071898BEQ36157440-4EECD3ED-768F-4730-B9FB-3643E02CA2A8Q36171750-27109030-B8FF-49E6-BFD4-E5AB142E439BQ36418745-F454D709-11BB-4672-AB5A-D6E4C540B3A1Q36420780-D978A3F2-CD9A-4A5D-89F0-D634DD2352F7Q36536861-B87BE25D-02F6-4424-9704-A70BBA9B09D9Q36677345-CFCC218E-94B2-4B1B-9FC6-3936276F7F24Q36708319-A22C0AC0-3F9F-4F64-BC21-90B875A61DACQ36722548-17B20CF0-7EA2-4DDF-9975-AAA7A368253AQ36759489-5C57B0EA-ABE9-4B93-86D1-ED86C12F2802Q36823592-788CDCF1-7888-4F08-A51F-EFB560A18E9CQ36859619-20BF5A85-CFB8-491F-9F84-C84FC973983BQ36864836-C91E257B-117F-4824-89FC-C10D964B6F13Q37007911-3ACAB357-06E5-4C67-9411-A30DD580FA85
P2860
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Safety analyses of adalimumab ...... nts with rheumatoid arthritis.
@ast
Safety analyses of adalimumab ...... nts with rheumatoid arthritis.
@en
type
label
Safety analyses of adalimumab ...... nts with rheumatoid arthritis.
@ast
Safety analyses of adalimumab ...... nts with rheumatoid arthritis.
@en
prefLabel
Safety analyses of adalimumab ...... nts with rheumatoid arthritis.
@ast
Safety analyses of adalimumab ...... nts with rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Safety analyses of adalimumab ...... nts with rheumatoid arthritis.
@en
P2093
A L Pangan
M H Schiff
S B Fitzpatrick
P2860
P304
P356
10.1136/ARD.2005.043166
P407
P577
2006-01-26T00:00:00Z